Drupal.behaviors.print = function(context) {window.print();window.close();}>
Pfizer to Shut Down Oligo Therapeutics Unit as Part of Restructuring
February 03, 2011
Pfizer to Shut Down Oligo Therapeutics Unit as Part of Restructuring
It was not immediately clear what impact the move would have on the programs overseen by the unit.
Full-text access for premium subscribers only.
Existing premium subscribers
login here
.
New to GenomeWeb?
Register here
quickly.
Related Stories
Oligo Drugs Advance in the Clinic in 2012 as Delivery Hurdles are Addressed
January 3, 2013 / Gene Silencing News
RNAi Field Looks to Late-Stage Clinical Data, Approvals to Regain Pharma Interest
January 3, 2013 / Gene Silencing News
Amid Advances in Lipid-Based Delivery, Some See Other Technologies Being Passed Over
January 13, 2011 / Gene Silencing News
In 2010, RNAi Moves into the Mainstream, microRNAs Continue to Garner Interest
January 6, 2011 / Gene Silencing News
Pfizer Amends In-House RNAi Rx Guidance
October 28, 2010 / Gene Silencing News